

22 September 2025

## Kidney Cancer

**Between 2022 to the present – have any patients who are/were being treated with a regimen of Lenvatinib and Pembrolizumab for metastatic papillary (or other non-renal cell) kidney cancer, received more than 16 cycles of Pembrolizumab in the BHSCT?  
If so, how many?**

<5 patients

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

**Between 2022 to the present – have any patients who are/were being treated with a regimen of Lenvatinib and Pembrolizumab for metastatic renal cell kidney cancer, received more than 16 cycles of Pembrolizumab in the BHSCT?  
If so, how many?**

<5 patients

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.